Merck & Co. said in a filing that Paul J. Diaz, managing partner at Cressey & Company, will join the company's Board of Directors effective Nov. 1, 2026.
Diaz will stand for election by Merck's shareholders in May 2027. With his addition, the Merck board will consist of 14 members.
Rob Davis, Merck's chairman and chief executive officer, said the company is pleased to welcome Diaz to the board, citing his leadership and business expertise in the healthcare industry.
Diaz is a managing partner at Cressey & Company, a private investment firm that invests in and cultivates healthcare firms. He previously served as president and chief executive officer of Myriad Genetics, Inc., a genetic testing and precision medicine company, and before that held the same roles at Kindred Healthcare, a Fortune 500 healthcare services company.
Diaz also serves on the Board of Centene Corporation, the Board of Trustees of Johns Hopkins Medicine, and the Board of Visitors of the Georgetown University Law Center. He holds a bachelor's degree in finance and accounting from American University and a J.D. from Georgetown University.